Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 3/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 17/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2824115 | 0.86 | ANPEP (0.48) | ANPEPPTGDR2 | |
| SCHEMBL2825476 | 0.84 | TP53 (0.41) | PTGDR2 | |
| SCHEMBL2825967 | 0.84 | ANPEP (0.48) | ANPEP | |
| SCHEMBL2825413 | 0.81 | ALDH1A1 (0.54) | — | |
| SCHEMBL29456287 | 0.81 | ALDH1A1 (0.54) | — | |
| SCHEMBL8705160 | 0.71 | ALDH3A1 (0.58) | — | |
| SCHEMBL661388 | 0.70 | HDAC1 (0.44) | PTGDR2 | |
| SCHEMBL29868403 | 0.70 | KMO (0.44) | PTGDR2 | |
| SCHEMBL661562 | 0.70 | KMO (0.44) | PTGDR2 | |
| SCHEMBL2335934 | 0.69 | HDAC6 (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1799643-B1 | INDOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB PHARMA SA (BE) | 2010-09-22 | — | — | EP | claimed |
| US-7632856-B2 | Indolone derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2009-12-15 | — | — | US | claimed |
| US-20090012147-A1 | Indolone Derivatives, Processes For Preparing Them And Their Uses | UCB PHARMA, S.A. (BE) | 2009-01-08 | — | — | US | claimed |
| EP-1799643-A1 | INDOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2007-06-27 | — | — | EP | claimed |
| WO-2006008067-A1 | INDOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2006-01-26 | — | — | WO | claimed |
| EP-1799643-B1 | INDOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB PHARMA SA (BE) | 2010-09-22 | — | — | EP | disclosed |
| EP-1799643-B1 | INDOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB PHARMA SA (BE) | 2010-09-22 | — | — | EP | disclosed |
| US-7632856-B2 | Indolone derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2009-12-15 | — | — | US | disclosed |
| US-7632856-B2 | Indolone derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2009-12-15 | — | — | US | disclosed |
| US-7632856-B2 | Indolone derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2009-12-15 | — | — | US | disclosed |
| US-20090012147-A1 | Indolone Derivatives, Processes For Preparing Them And Their Uses | UCB PHARMA, S.A. (BE) | 2009-01-08 | — | — | US | disclosed |
| US-20090012147-A1 | Indolone Derivatives, Processes For Preparing Them And Their Uses | UCB PHARMA, S.A. (BE) | 2009-01-08 | — | — | US | disclosed |
| US-20090012147-A1 | Indolone Derivatives, Processes For Preparing Them And Their Uses | UCB PHARMA, S.A. (BE) | 2009-01-08 | — | — | US | disclosed |
| EP-1799643-A1 | INDOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006008067-A1 | INDOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2006-01-26 | — | — | WO | disclosed |
| WO-2006008067-A1 | INDOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012147-A1 | Indolone Derivatives, Processes For Preparing Them And Their Uses | IDO1, IDO2, HTR3C | ANPEP 2230/4885PTGDR2 716/4885AKR1B1 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.